| Last Name | Name | Awards | Contact | |
|---|---|---|---|---|
| Shi | Guixin Shi | 3 | ||
| BENCHIMOL | MICHAEL BENCHIMOL | 1 | ||
| WANG | ZHIYONG WANG | 2 |
Phase 2 SBIR
Umbilical cord blood (UCB) has been an alternative source for patients with hematologic diseases who may be potentially cured by allogeneic hematopoietic cell transplantation. In addition, UCB is an important stem cell source for other promising technologies, such as large-scale ex vivo productions of hematopoietic stem cell (HSC)-derived red bl...
Phase 2 SBIR
? DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a simple, robust, and cost-efficient circulating tumor cell (CTC) isolation system based on an innovative BUBLES (BUoyancy enaBLEd Separation) technology for point-of- care applications. The feasibility of this technology has been recently established by using ...
Phase 2 SBIR
DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a simple, robust, and cost-efficient circulating tumor cell (CTC) isolation system based on an innovative BUBLES (BUoyancy enaBLEd Separation) technology for point-of- care applications. The feasibility of this technology has been recently established by using targ...
Phase 1 SBIR
DESCRIPTION (provided by applicant): Substitution of abnormal stem cells with healthy cells has been accomplished clinically through hematopoietic stem cell (HSC) transplantation for more than 50 years. Umbilical cord blood (UCB) is an alternative to bone marrow or peripheral blood HSC source for patients with hematologic diseases who need allog...
Phase 1 SBIR
Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time;(b) low final sample volume;(c) isolation from large blood volume;(d) low carryover of leukocytes and ...
Phase 1 SBIR
Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time;(b) low final sample volume;(c) isolation from large blood volume;(d) low carryover of leukocytes and ...
